HBMHF (HBM Holdings) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBMHF HBM Holdings Ltd HBMHF
73 GF Score
Price $1.56
GF Value $0.87
! 4 Warning Signs
View Full Analysis

What is HBM Holdings FFO?

FFO (Funds from operations) only applies to REITs.

HBMHF
73GF Score
HBM Holdings Ltd HBMHF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HBM Holdings (HBMHF) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.

Key valuation signals for HBMHF:

  • FFO:
  • GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HBM Holdings Business Description

Other Exchanges 02142:Hong Kong6XY:Germany
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score

Get the complete analysis for HBMHF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price
$0.87
GF Value